H. Bérard

2.4k total citations
55 papers, 1.1k citations indexed

About

H. Bérard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, H. Bérard has authored 55 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 9 papers in Surgery. Recurrent topics in H. Bérard's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (7 papers). H. Bérard is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (7 papers). H. Bérard collaborates with scholars based in France, United States and Japan. H. Bérard's co-authors include I. Monnet, J Lecomte, C. Chouaïd, H. Le Caer, G. Robinet, A. Vergnenègre, H. Léna, Nathalie Fretault, P. Bäumer and Fabrice Barlési and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

H. Bérard

52 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Bérard France	19	655	649	145	141	120	55	1.1k
Manuela Giangreco Italy	14	282 0.4×	203 0.3×	64 0.4×	89 0.6×	86 0.7×	55	774
Seok Hyun Kim South Korea	17	151 0.2×	233 0.4×	48 0.3×	195 1.4×	169 1.4×	86	809
Linda Wedlake United Kingdom	19	371 0.6×	336 0.5×	39 0.3×	191 1.4×	441 3.7×	30	1.4k
Vickie R. Shannon United States	23	626 1.0×	588 0.9×	71 0.5×	289 2.0×	160 1.3×	62	1.4k
Andrea Lisotti Italy	21	682 1.0×	515 0.8×	33 0.2×	566 4.0×	755 6.3×	110	1.6k
David Kastenberg United States	15	668 1.0×	572 0.9×	27 0.2×	75 0.5×	415 3.5×	48	1.0k
Iyad Kabar Germany	19	144 0.2×	218 0.3×	74 0.5×	217 1.5×	443 3.7×	54	1.0k
Sadhna Dhingra United States	18	153 0.2×	290 0.4×	26 0.2×	158 1.1×	305 2.5×	58	965
R. Waldron Ireland	14	349 0.5×	213 0.3×	102 0.7×	117 0.8×	286 2.4×	30	884
Mark M. Aloysius United States	16	242 0.4×	90 0.1×	206 1.4×	188 1.3×	370 3.1×	64	884

Countries citing papers authored by H. Bérard

Since Specialization

Citations

This map shows the geographic impact of H. Bérard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Bérard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Bérard more than expected).

Fields of papers citing papers by H. Bérard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Bérard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Bérard. The network helps show where H. Bérard may publish in the future.

Co-authorship network of co-authors of H. Bérard

This figure shows the co-authorship network connecting the top 25 collaborators of H. Bérard. A scholar is included among the top collaborators of H. Bérard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Bérard. H. Bérard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bérard, H., et al.. (2024). Evaluation algorithmique inclusive de la qualité des espaces publics. SHILAP Revista de lepidopterología. 203. 1005–1005. 1 indexed citations

Bérard, H., et al.. (2021). Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S. Cancer Genetics. 256-257. 158–161. 3 indexed citations

Locher, Chrystèle, N. Pourel, H. Le Caer, et al.. (2018). Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: An open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer. 121. 25–29. 9 indexed citations

Barlési, Fabrice, Makoto Nishio, Manuel Cobo, et al.. (2018). IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii743–viii744. 44 indexed citations

Caer, H. Le, Isabelle Borget, R. Corre, et al.. (2017). Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. Journal of Thoracic Disease. 9(10). 3747–3754. 13 indexed citations

Greillier, Laurent, Julien Mazières, I. Monnet, et al.. (2015). Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer. 15(1). 857–857. 14 indexed citations

Gervais, Radj, H. Le Caer, I. Monnet, et al.. (2014). Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501. Clinical Lung Cancer. 16(2). 100–105. 10 indexed citations

Treut, J. Le, H. Léna, P.-J. Souquet, et al.. (2013). Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Annals of Oncology. 24(6). 1548–1552. 111 indexed citations

Chouaïd, C., H. Le Caer, R. Corre, et al.. (2012). Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505). Clinical Lung Cancer. 14(2). 103–107. 12 indexed citations

10.

Paleiron, N., M. André, C. Chouaïd, et al.. (2012). Évaluation de la ventilation non invasive préopératoire avant chirurgie de résection pulmonaire. Étude préOVNI GFPC 12-01. Revue des Maladies Respiratoires. 30(3). 231–237. 1 indexed citations

11.

Barlési, Fabrice, R. Gervais, H. Léna, et al.. (2011). Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Annals of Oncology. 22(11). 2466–2470. 181 indexed citations

12.

Decroisette, C., I. Monnet, H. Bérard, et al.. (2011). Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601). Journal of Thoracic Oncology. 6(3). 576–582. 97 indexed citations

13.

Vergnenègre, A., R. Corre, H. Bérard, et al.. (2010). Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study. Journal of Thoracic Oncology. 6(1). 161–168. 27 indexed citations

14.

Descourt, R., A. Vergnenègre, Fabrice Barlési, et al.. (2010). Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study. Journal of Thoracic Oncology. 6(2). 351–357. 18 indexed citations

15.

Bérard, H., et al.. (2008). Un effet indésirable grave du traitement antituberculeux : la thrombopénie au pyrazinamide. Revue des Maladies Respiratoires. 25(9). 1142–1144. 2 indexed citations

16.

Cortot, Alexis B., L. Gérinière, G. Robinet, et al.. (2006). Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Annals of Oncology. 17(9). 1412–1417. 35 indexed citations

17.

Bérard, H., et al.. (2005). Multicenter Phase II Trial of Carboplatin/Vinorelbine in Elderly Patients with Advanced Non–Small-Cell Lung Cancer–Efficacy and Impact on Quality of Life: Groupe Français de Pneumo-Cancérologie Study 9902. Clinical Lung Cancer. 7(2). 114–120. 9 indexed citations

18.

Bérard, H., et al.. (1999). Comparison of racecadotril and loperamide in adults with acute diarrhoea. Alimentary Pharmacology & Therapeutics. 13(s6). 21–26. 31 indexed citations

19.

Rogé, J, P. Bäumer, H. Bérard, J.C. Schwartz, & J Lecomte. (1993). The Enkephalinase Inhibitor, Acetorphan, in Acute Diarrhoea: A Double-Blind, Controlled Clinical Trial versus Loperamide. Scandinavian Journal of Gastroenterology. 28(4). 352–354. 54 indexed citations

20.

Bérard, H., et al.. (1993). Action of enkephalinase (EC 3.4.24.11) inhibition on the pre- and post-prandial electromyographic patterns of colon in rats. Neuropeptides. 24(5). 299–305. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact